<DOC>
	<DOC>NCT01524497</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of trazodone hydrochloride prolonged-release tablets for treatment of depression in Chinese population.</brief_summary>
	<brief_title>A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Trazodone</mesh_term>
	<criteria>1. Age between 18 and 65, males and females, outpatients or inpatients; 2. Single episode or recurrent depression according to DSMIV (Version 4) criteria; 3. Scores &gt; 18 on 17item HAMD at screening and baseline visits with a decrease not exceeding 20% between the two visits; 4. Symptoms of depression for at least 1 month; 5. Patients or their dependents/guardians providing signed informed consent forms. 1. Serious suicide attempts (â‰¥ 3 on item 3 'Suicide' of HAMD); 2. Depressive episode, with psychotic symptoms; 3. Refractory depression; 4. Depressive episode secondary to other mental or physical disorders; 5. Bipolar disorder; 6. Significant reduction in body weight and malnutrition induced by major depression; 7. Serious or unstable heart, hepatic, renal, endocrine and hematologic disease or malignant tumors;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>losing interest and feelings of guilt</keyword>
	<keyword>poor concentration</keyword>
	<keyword>loss of appetite</keyword>
	<keyword>suicide</keyword>
</DOC>